NCT04274738View on ClinicalTrials.gov

A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

April 30, 2020

Primary Completion Date

October 31, 2022

Study Completion Date

October 31, 2022

Conditions
Waldenstrom's Macroglobulinemia
Interventions
DRUG

Mavorixafor

Mavorixafor capsules will be administered per dose and schedule specified in the arm.

DRUG

Ibrutinib

Ibrutinib capsules will be administered per dose and schedule specified in the arm.

Trial Locations (5)

11528

University of Athens, Athens

77030

MD Anderson Cancer Center, Houston

80215

Colorado Blood Cancer Institute, Denver

02114

Dana Farber Cancer Institute, Boston

Mass General Hospital Cancer Center, Boston

Sponsors

Lead Sponsor

X4 Pharmaceuticals
All Listed Sponsors
lead

X4 Pharmaceuticals

INDUSTRY

NCT04274738 - A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4 | Biotech Hunter | Biotech Hunter